Which medication is best for wet macular degeneration?

Johns Hopkins University School of Medicine researchers studied the ocular as well as systemic effects that three anti-VEGF therapies had on patients. Pegatanib, ranibizumab and bevacizumab were all compared to patients who received no anti-VEGF treatments Researchers evaluated specific studies from databases and focused on 16 randomized controlled trials that had a total of 6347 […]

Revolutionary treatment restores vision

A study that involved a revolutionary treatment using stem cells from the eyes of non-living donors is detailed in STEM CELLS Translational Medicine. Researchers hope that this pioneering treatment may hold the key to finding a cure for blindness that is caused by damage to the cornea. Eight patients with condition known as Limbal stem […]

Gene therapy used to treat AMD

A surgeon at the John Radcliffe Hospital in the UK successfully injected a synthetic gene into a patient’s eye in the hope of stopping the progression of age-related macular degeneration. The patient, Janet Osborne, is the first person to receive the gene therapy in the trial that is being conducted at the John Radcliffe Hospital […]

Time-release coating developed to keep AMD drug in eye longer

A new drug-delivery system developed by a team of biomedical engineers at Johns Hopkins will enable a new wet macular degeneration drug to stay in the eye longer meaning fewer injections. The research team tested their new drug and its time-release coating in mice that had similar eye abnormalities as are found in people with […]

The latest retinal eye treatment is a TRAP!

A new treatment for eye disease is designed to bind all forms of Vascular Endothelial Growth Factor-A (VEGF-A) and Placental Growth Factor (PLGF) proteins which play a part in the abnormal growth of new blood vessels. It is known as VEGF Trap-Eye.